This dual requirement—multiplex knock-out for immune evasion and large, precise knock-in for therapeutic function—creates a compounding engineering challenge. While knock-out technologies have advanced rapidly, as can be seen in the rapid evolution of CRISPR systems, knock-in remains a major bottleneck. Conventional approaches such as viral vectors or transposon systems introduce payloads in a semi-random manner, leading to variable expression, potential silencing, and safety concerns related to insertional mutagenesis [7, 8]. Just as importantly, these approaches are poorly suited for large or multi-gene constructs and lack the precision required for next-generation therapies.

As a result, developers face a paradox—the biology of durable cell therapy demands increasingly sophisticated genetic programs, but the tools available to install those programs had been limiting.

This challenge is particularly evident in emerging allogeneic platforms such as induced pluripotent stem cells (iPSCs). These systems offer a scalable, universal starting material that can be engineered once and deployed across multiple indications. However, realizing this vision depends on the ability to introduce complex genetic payloads in a precise, reproducible, and stable manner—without compromising cell fitness or safety.

This is where site-specific technologies that can handle large DNA fragments become essential.